ANAB

ANAB

USD

AnaptysBio Inc. Common Stock

$34.740-1.230 (-3.420%)

实时价格

Healthcare
生物技术
美国

价格图表

Loading Chart...

关键指标

市场指标
公司基本面
交易统计

市场指标

开盘价

$35.970

最高价

$36.500

最低价

$34.595

成交量

0.76M

公司基本面

市值

971.8M

所属行业

生物技术

国家/地区

United States

交易统计

平均成交量

0.52M

交易所

NMS

货币

USD

52周价格范围

最低价 $12.21当前价 $34.740最高价 $38.385

相关新闻

GlobeNewswire

Anaptys Announces Third Quarter 2025 Financial Results and Provides Business Update

Announced intent to separate biopharma operations from substantial royalty assets by YE 2026Phase 2 top-line data through Week 12 for rosnilimab, a pathogenic T cell depleter, in ulcerative colitis on track for Nov./Dec.

查看更多
Anaptys Announces Third Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire

Anaptys Announces Participation in November Investor Conferences

SAN DIEGO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (NASDAQ:ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president

查看更多
Anaptys Announces Participation in November Investor Conferences
Analyst Upgrades

Stifel Maintains Buy on AnaptysBio, Raises Price Target to $80

Stifel analyst Alex Thompson maintains AnaptysBio with a Buy and raises the price target from $55 to $80.

查看更多
Stifel Maintains Buy on AnaptysBio, Raises Price Target to $80
GlobeNewswire

Anaptys Announces New Positive Phase 2b Trial Results for Rosnilimab in Rheumatoid Arthritis at ACR Late-Breaking Oral Presentation

New data reinforce rosnilimab's efficacy profile in rheumatoid arthritis (RA) with deepening of clinical responses, including CDAI remission, from Week 12 to Week 28 regardless of prior advanced therapy, including

查看更多
Anaptys Announces New Positive Phase 2b Trial Results for Rosnilimab in Rheumatoid Arthritis at ACR Late-Breaking Oral Presentation